Vivos Therapeutics, Inc.

NasdaqCM VVOS

Vivos Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2024: USD 2.56 M

Vivos Therapeutics, Inc. Total Non-Current Liabilities is USD 2.56 M for the quarter ending September 30, 2024, a -17.65% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Vivos Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2023 was USD 3.10 M, a 20.26% change year over year.
Vivos Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2022 was USD 2.58 M, a 616.94% change year over year.
Vivos Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2021 was USD 360.00 K, a -89.46% change year over year.
Vivos Therapeutics, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2020 was USD 3.41 M.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NasdaqCM: VVOS

Vivos Therapeutics, Inc.

CEO	Mr. R. Kirk Huntsman
IPO Date	Dec. 11, 2020
Location	United States
Headquarters	9137 Ridgeline Boulevard
Employees	114
Sector	Healthcare
Industries Dental Care 3D Printing Biotechnology Clinical Trials Medical Instruments Telehealth

Description

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

Key trends

Past 5 years